| O |
|
Obesity and coagulation. Is there any correlation?
|
| Koziri A., Avramakis G., Sfiridaki K., Zaharaki A., Georgas G., Tsoutsoumanou K., Defiloppis L., Manousakis E., Lambrogiannakis E., Nikolaidis G. |
| |
|
Objective assessment of deep vein thrombosis and pulmonary embolism can be deferred without increased risk of thrombosis: a practical approach based on the pretest clinical model, d-dimer and the use of low molecular weight heparins
|
| Siragusa S., Granzow K., Anastasio R., Falaschi F., Porta C., Palmieri P. N., Malato A., Gamba G., Minardi V., Bressan M. A., Mariani G. |
| |
|
Observation of preventive and therapeutic effects of anti-thrombin-III on experimental disseminated intravascular coagulation
|
| Wensheng L., Su J. |
| |
|
Observation on behavioral and hematological stress parameters tending to disappear after injections of unfractionary heparin
|
| Kondashevskaya M. |
| |
|
Observations on immunoadsorption (IA) as an auxiliary therapy for acquired thrombotic thrombocytopenic purpura (TTP)
|
| Studt J. D., Mansouri Taleghani B., Fontana S., Kremer Hovinga J. A., Lämmle B. |
| |
|
Observer variability in the assessment of clinical probability in patients with suspected pulmonary embolism
|
| Leclercq M., Kruip M. J. H. A., Mac Gillavry M. R., Van Marwijk Kooy M. R., Buller H. R. |
| |
|
Occurrence and management of abciximab induced pseudothrombocytopenia
|
| Karnicki K., Mcbane R. D., Miller R. S., Owen W. G. |
| |
|
Occurrence of myocardial infarction and PAI-1 4G/5G and ACE I/D gene polymorphisms in patients on chronic dialysis
|
| Margaglione M., Aucella F., Vigilante M., Gatta G., Colaizzo D., Forcella M., Ktena M., Procaccini D., Salatino G., De Min A., Grandone E., Stallone C. |
| |
|
On the role of platelets, and homocysteine in thrombotic patients, healthy controls and mutant carriers of methylentetrahydrofolate reductase (‘MTHFR’) (C677T)
|
| Schenk J. F., Ames M., Pindur G., Stephan B., Seyfert U. T. |
| |
|
Opposing effects of P-selectin and PECAM-1 on arterial thrombus growth and stability in vivo
|
| Falati S., Patil S., Gibbins J., Gross P. L., Merrill-Skoloff G., Weiler H., Cooley B., Newman D. K., Newman P. J., Furie B. C., Furie B. |
| |
|
Optimal concentrations of inhibitors, zymogens and procofactors of coagulation
|
| Tyurin K. |
| |
|
Optimal duration of oral anti-coagulant therapy after the first episode of deep vein thrombosis of the lower limbs: a randomized study based on the recanalization of the veins detected by ultrasonography
|
| Sirgausa S., DACUS, INVESTIGATORS |
| |
|
Optimal intensity of oral anti-coagulant therapy in patients with mechanical heart valves
|
| Vink R., Kraaijenhagen R. A., Hutten B. A., Brink Van Den R. B. A., Mol De B. A., Levi M. |
| |
|
Optimisation of thrombin inhibition: beliefs and facts
|
| Samama M.M. |
| |
|
Optimization model for type IV collagen degradation: determination of kinetic constants
|
| Tyurin K., Ignatiev D. yU., Bukharov I. B., Khanin M. |
| |
|
Optimization of factor VIII clotting assays: evaluation of VWF content in FVIII-deficient plasma and effect of albumin in dilution buffer
|
| Weston S. B., Komusin P. J., Jankowski M. A. |
| |
|
Optimization of human 14 000 oligonucleotide-microarrays and study design for the evaluation of gene expression profiling in cardiovascular diseases
|
| Giusti B., Gori A. M., Rossi L., Bandinelli B., Lucarini L., Evangelisti L., Lapini I., Lenti M., Abbate R., Pepe G. |
| |
|
Oral anti-coagulant therapy with POC device and remote computer monitoring in the setting of the Italian National Health System (INHS)
|
| Paccamiccio E., Trottini S., Rosafalco M., Filippucci E., Duca E., Vecchioli M., Nenci G. G., Iorio A. |
| |
|
Oral anti-coagulation and dental extraction
|
| Correa M. E. P., Alves F. A., Scalet P., Aranha F. J. P., Ozelo M. C., Annicchinnio-Bizzacchi J. M. |
| |
|
Oral anti-coagulation in elderly patients in clinical practice: 187 patients
|
| Mahé I., Grenard A. S., Joyeux N., Simoneau G., Caulin C., Bergmann J. F. |
| |
|
Oral anticoagulation telemedicine management system: the MC-SAT project
|
| Piovella F., Germagnoli F., Barone M., Cristiani P., Stoppini A., Sabatini F., Librè L., Piovella C., Mansour H. |
| |
|
Oral antithrombin agents comprise the regulatory functions of thrombin
|
| Fareed D., Bacher P., Hoppensteadt D., Walenga J. M., Ma Q., Bick R. |
| |
|
Oral contraceptives decrease the sensitivity of plasma for the anticoagulant activity of activated protein C (APC) by decreasing plasma glucosylceramide (GlcCer) level
|
| Deguchi H., Bouma B. N., Middeldorp S., Lee Y. M., Griffin J. H. |
| |
|
Oral direct thrombin inhibition, a promising new approach
|
| Haas S. |
| |
|
Oral factor VIII concentrate for immune tolerance induction: preliminary study of safety in a high responder inhibitor patient
|
| Gill J. C., Montgomery R. R. |
| |
|
Oral infection as a risk factor of atherosclerosis: first results of an intervention study
|
| Lösche W., Marshall G. J., Krause S., Schubert K., Kocher T., Kinane D. |
| |
|
Oral not transdermal estrogen replacement therapy is associated with venous thromboembolism risk
|
| Scarabin P., Oger E., Plu-Bureau G., for the Estrogen and Thromboembolism Risk (ESTHER) Study Group |
| |
|
Oral SNAC-heparin vs. enoxaparin for preventing venous thromboembolism following total hip replacement
|
| Hull R. D., Kakkar A. K., Marder V. J., Pineo G. F., Goldberg M. M., Raskob G. E., for the PROTECT Trial Investigators¶ |
| |
|
Orally active integrin antagonists perturb aIIbb3 integrin conformation
|
| Hantgan R. R., Mousa S. A., Feuerstein G. Z. |
| |
|
Outcome measures in hemophilia: a physician's perspective
|
| Van Der Berg M. |
| |
|
Overall hemostasis and thrombin activatable fibrinolysis inhibitor (TAFI) – dependent fibrinolysis in patients treated with the novel oral thrombin inhibitor – ximelagatran
|
| Antovic J., Schulman S., Antovic A., Blombäck M. |
| |
|
Overexpression of basic fibroblast growth factor (bFGF) in the bone marrow of patients with acute myeloid leukemia: a potential role for bFGF as an autocrine growth factor
|
| Bieker R., Padro T., Kramer J., Steins M., Kessler T., Retzlaff S., Kienast J., Berdel W. E., Mesters R. M. |
| |
|
Overexpression of PAI-1 prevents abdominal aortic aneurysm development
|
| Qian H. S., Freay A., Liu P., Kauser K., Morser J. M., Dole W. P., Deng G. G. |
| |
|
Overexpression of the platelet P2X1 ion channel in transgenic mice generates a novel prothrombotic phenotype
|
| Oury C., Kuijpers M., Toth-Zsamboki E., Bonnefoy A., Danloy S., Vreys I., Feijge M., De Vos R., Vermylen J., Heemskerk J. W. M., Hoylaerts M. F. |
| |
|
Oxidation products of common phospholipid specifically impair the activity and the reactivity of tissue factor pathway inhibitor
|
| Ohkura N., Horie S., Hamuro T., Kamikubo Y., Matsuda J. |
| |
|
Oxidized phospholipids in oxidized LDL down-regulate thrombomodulin transcription in vascular endothelial cells through a decrease in the binding of RAR
|
| Ishii I.H., Takada K. T., Horie S. H., Oida K. O. |
| |
|
Oxidized phospholipids induce proatherogenic genes in murine carotid arteries
|
| Fuernkranz A., Botchkov V., Kadl A., Binder B. R., Leitinger N. |
| |
|
Oxidized phospholipids induce the human heme oxygenase-1 via CREB: a feedback mechanism in inflammatory disorders
|
| Kroenke G., Bochkov V., Fürnkranz A., Kadl A., Binder B. R., Leitinger N. |
| |
|
Oxidized phospholipids inhibit action of endotoxin in vitro and in vivo
|
| Bochkov V. N., Gruber F., Binder B. R., Leitinger N. |
| |
|
OxiLDL/b2GPI complexes are frequent in SLE whereas autoantibodies to oxLig-1/b2GPI are more prevalent in patients with antiphospholipid syndrome
|
| Lopez D., Garcia-Valladares I., Palafox-Sanchez C., Matsuura E., Garcia De La Torre I., Lopez L. R. |
| |
